Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel

[1]  H. Suryapranata,et al.  Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor , 2015, Journal of cardiovascular pharmacology.

[2]  M. Hadamitzky,et al.  Predictors of antiplatelet response to prasugrel during maintenance treatment , 2015, Platelets.

[3]  P. Morange,et al.  Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. , 2014, International journal of cardiology.

[4]  I. Xanthopoulou,et al.  Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. , 2014, American heart journal.

[5]  M. Olschewski,et al.  A high ratio of ADP–TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone , 2014, Clinical Research in Cardiology.

[6]  C. Bode,et al.  Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry , 2013, Thrombosis and Haemostasis.

[7]  A. Loundou,et al.  Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. , 2014, The American journal of cardiology.

[8]  K. Huber,et al.  Response variability to P2Y12 receptor inhibitors: expectations and reality. , 2013, JACC. Cardiovascular interventions.

[9]  G. Maurer,et al.  Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. , 2013, International journal of cardiology.

[10]  E. Vicaut,et al.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting. , 2012, The New England journal of medicine.

[11]  D. Prabhakaran,et al.  Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. , 2012, JAMA.

[12]  G. Stone,et al.  A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem , 2012, Journal of the American College of Cardiology.

[13]  D. Aradi,et al.  Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention , 2012, Journal of Thrombosis and Thrombolysis.

[14]  S. Werns.  Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial , 2012 .

[15]  R. Koppensteiner,et al.  The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. , 2011, Thrombosis research.

[16]  Y. Jeong,et al.  Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction. , 2010, Thrombosis research.

[17]  Deepak L. Bhatt,et al.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.

[18]  B. Giusti,et al.  Clopidogrel non-responsiveness and risk of cardiovascular morbidity , 2010, Thrombosis and Haemostasis.

[19]  C. Bode,et al.  Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes , 2010, Basic Research in Cardiology.

[20]  K. Winters,et al.  Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease , 2009, Journal of clinical pharmacy and therapeutics.

[21]  R. Koppensteiner,et al.  Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation , 2009, Thrombosis and Haemostasis.

[22]  B. Baker,et al.  The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. , 2008, Journal of the American College of Cardiology.

[23]  S. Duffull,et al.  What is the best size descriptor to use for pharmacokinetic studies in the obese? , 2004, British journal of clinical pharmacology.

[24]  C. Macaya,et al.  Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? , 2004, The Journal of invasive cardiology.

[25]  J. Necciari,et al.  Cirrhosis Does Not Affect the Pharmacokinetics and Pharmacodynamics of Clopidogrel , 2000, Journal of clinical pharmacology.